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Abstract: A better understanding of the metabolic constraints of a tumor may lead to more effective
anticancer treatments. Evidence has emerged in recent years shedding light on a crucial aspartate
dependency of many tumor types. As a precursor for nucleotide synthesis, aspartate is indispensable
for cell proliferation. Moreover, the malate–aspartate shuttle plays a key role in redox balance, and a
deficit in aspartate can lead to oxidative stress. It is now recognized that aspartate biosynthesis is
largely governed by mitochondrial metabolism, including respiration and glutaminolysis in cancer
cells. Therefore, under conditions that suppress mitochondrial metabolism, including mutations,
hypoxia, or chemical inhibitors, aspartate can become a limiting factor for tumor growth and cancer
cell survival. Notably, aspartate availability has been associated with sensitivity or resistance to
various therapeutics that are presently in the clinic or in clinical trials, arguing for a critical need for
more effective aspartate-targeting approaches. In this review, we present current knowledge of the
metabolic roles of aspartate in cancer cells and describe how cancer cells maintain aspartate levels
under different metabolic states. We also highlight several promising aspartate level-modulating
agents that are currently under investigation.
Keywords: oxidative phosphorylation; mitochondrial respiration; mitochondrial DNA mutation;
hypoxia; aspartate; glutaminase; asparagine; GOT1; alpha-ketoglutarate; cancer metabolism
1. Introduction
Most types of cancer cells rely on both mitochondrial metabolism and glycolysis [1,2].
While a high glucose flux via glycolysis and its parallel pathway, the pentose phosphate
pathway (PPP), can provide copious amounts of ATP for energy, NADPH for redox balance,
and ribose-5-phosphate for nucleotide synthesis, the mitochondrial tricarboxylic acid (TCA)
cycle generates other intermediates necessary for the biosynthesis of amino acids, lipids,
heme, and nucleotides [1–3]. Therefore, to fuel the TCA cycle via glutaminolysis, many
cancer cell types exhibit glutamine dependency [1,2,4]. As both glycolysis and the TCA
cycle require a steady supply of electron acceptors, mitochondrial respiration (also known
as oxidative phosphorylation (OXPHOS)), which recycles NADH into NAD+ via the
electron transport chain (ETC), is critical for continuous nutrient oxidation in the cell [3].
Moreover, it has recently been demonstrated in two seminal papers by Birsoy et al. and
Sullivan et al. that a primary role of mitochondrial respiration is to produce aspartate [5,6].
Aspartate is vital for multitudinous needs of a proliferating cell, being not only a
proteinogenic amino acid, but also a major substrate for de novo synthesis of purines and
pyrimidines [7]. Cellular import of aspartate appears limited to the brain and a subset of
cancer cells [5,8]. Therefore, most cells can synthesize aspartate via mitochondrial glutamic-
oxaloacetic transaminase 2 (GOT2), which uses the TCA cycle metabolite oxaloacetate
as a substrate [5]. Aspartate production is thus fundamentally coupled to mitochondrial
Biomolecules 2021, 11, 1666. https://doi.org/10.3390/biom11111666 https://www.mdpi.com/journal/biomolecules
Biomolecules 2021, 11, 1666 2 of 11
oxidative metabolism and respiration. Once generated in the mitochondrion, aspartate
can be exported to the cytosol where it participates in myriad metabolic and biosynthetic
pathways [9].
Upon being recognized by researchers for its pivotal role in cell proliferation and via-
bility, a number of recent studies have also begun to uncover that aspartate levels in cancer
cells are associated with the efficacy of various anticancer therapeutic approaches, including
chemotherapy, targeted therapy, OXPHOS inhibition, and glutamine deprivation [10–13].
Moreover, encouraging preclinical results on the development of new aspartate-targeting
agents are also coming to light [14,15]. Thus, a systematic review of these findings may
help illuminate the path forward in the search for more effective anticancer strategies.
2. Roles of Aspartate in Cell Proliferation and Survival
2.1. Protein Synthesis, Amino Acid Metabolism, and the Urea Cycle
One of the important roles of aspartate in governing cell proliferation is by supporting
protein and amino acid synthesis (Figure 1). Aspartate is one of the 20 proteinogenic
amino acids and also serves as a precursor for the biosynthesis of asparagine and arginine.
Asparate gives rise to asparagine via asparagine synthetase (ASNS). It has been shown
that intracellular asparagine levels are a critical determinant of mTOR activities [16,17].
Although not all cancer cells express ASNS, such as acute lymphoblastic leukemia (ALL)
blasts that mostly rely on exogenous asparagine supplies [18], in some cancer types ASNS
expression has been linked to tumor progression [19,20]. In addition, aspartate is a nitrogen
donor for arginine. Metabolism from aspartate to arginine is part of the urea cycle [21],
whereby aspartate first reacts with citrulline via argininosuccinate synthase (ASS1) to
produce argininosuccinate, which is subsequently converted into arginine and fumarate
via argininosuccinate lyase (ASL). Notably, many malignancies exhibit downregulation
of various urea cycle enzymes, including ASS1 [21]. ASS1 deficiency promotes cell prolif-
eration by diverting aspartate for pyrimidine synthesis [22]. Increases in aspartate levels
can also lead to activation of mTOR [22]. These results demonstrate that suppression of
the urea cycle, even though it can cause arginine auxotrophy [21], provides an overall
proliferation advantage to cancer cells through increased aspartate availability.
Biomolecules 2021, 11, x FOR PEER REVIEW 3 of 12 
 
further imply that investigators may need to consider the possible contribution of stroma-
derived aspartate to cancer cell metabolism during the development of effective aspartate-
targeting approaches. 
 
Figure 1. Roles of aspartate in cell proliferation and survival. The diagram outlines the major biosynthetic and redox 
pathways in which aspartate is required and the potential consequences when aspartate level is insufficient. ASNS, aspar-
agine synthase; ASS1, argininosuccinate synthase 1; MAS, malate–aspartate shuttle; ME1, malic enzyme 1. 
2.3. Redox Balance and Oxidative Stress 
Another prominent metabolic role of aspartate is to regulate cell compartmental re-
dox balance via the malate–aspartate shuttle (MAS) (Figure 1). The net effect of the MAS 
is to recycle NADH produced in the cytosol (predominantly from glycolysis) back to 
NAD+ and to transfer the reducing power generated in the cytosol to the mitochondrion 
for oxidation via oxidative phosphorylation [23]. The MAS utilizes two cytosolic enzymes, 
glutamic-oxaloacetic transaminase 1 (GOT1) and malate dehydrogenase 1 (MDH1), to 
convert aspartate to malate, NADH to NAD+, and alpha-ketoglutarate (aKG; also known 
as 2-oxoglutarate) to glutamate. It utilizes another two enzymes in the mitochondria, 
GOT2 and MDH2, which in a fashion that is parallel and reverse to the cytosolic reaction, 
convert malate to aspartate, NAD+ to NADH, and aKG to glutamate [5]. The MAS also 
requires two antiporters on the mitochondrial inner membrane to transport the metabo-
lites in and out of the mitochondria [23]. Evidence suggests that disruption of the MAS 
may decrease the cytosolic NAD+/NADH ratio and increase the mitochondrial 
NAD+/NADH ratio, which could lead to rippling effects on other metabolic pathways [9]. 
Moreover, some cancer types, such as those carrying PI3KCA mutations, appear to be 
more sensitive to MAS perturbation than others [24,25]. 
Interestingly, in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) cells, as-
partate also plays an important role in maintaining redox homeostasis by supporting 
NADPH production [26] (Figure 1). As discussed above, aspartate is an important source 
for malate in the cytosol. In PDAC cells, malate is utilized by NADP-dependent malic 
enzyme 1 (ME1) to generate pyruvate and NADPH. Inhibition of any step in the produc-
tion and utilization of cytosolic malate leads to a decrease in the NADPH/NADP+ ratio, 

























Aspartate    Malate








Figure 1. Roles of asp rt te in cell proliferatio rvival. The diagram outlines the maj r biosynthetic and redox
pathways in which aspartate is required and the potential consequences when aspartate level is insufficient. ASNS,
asparagine synthase; ASS1, argininosuccinate synthase 1; MAS, malate–aspartate shuttle; ME1, malic enzyme 1.
Biomolecules 2021, 11, 1666 3 of 11
2.2. De Novo Nucleotide Synthesis
Proliferating cells have a high demand for nucleotides due to their robust DNA
replication, RNA transcription, and ribosome biogenesis. Aspartate is a key building
block for both purines and pyrimidines [7], contributing to three carbon atoms and one
nitrogen atoms of the rings in uracil, cytosine, and thymine [7]. It also contributes to two
purine biosynthesis steps including the conversions of 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) into succino-AICAR (SAICAR) and of inosine monophosphate
(IMP) into adenylosuccinate [7]. Aspartate deprivation can result in nucleotide deficiency,
DNA replication stress, and mTOR inactivation [12,14,15] (Figure 1).
In addition to cell proliferation, de novo nucleotide synthesis plays a critical role
in cancer cells’ response to drugs. While studying the emergence of chemoresistant and
relapse-initiating acute myeloid leukemia (AML) cells using a mouse model, van Gastel et al.
found that induction chemotherapy could instigate significant metabolic changes in the
stroma, resulting in its increased aspartate production and secretion [13]. Aspartate exited
from the stroma could enter AML cells and increase nucleotide synthesis in these cells [13].
Consequently, inhibition of pyrimidine synthesis led to selective elimination of post-chemo
relapse-initiating leukemia cells in the blood [13], suggesting that aspartate-lowering agents
may in some cases reduce the advent of chemoresistance. These results further imply that
investigators may need to consider the possible contribution of stroma-derived aspartate to
cancer cell metabolism during the development of effective aspartate-targeting approaches.
2.3. Redox Balance and Oxidative Stress
Another prominent metabolic role of aspartate is to regulate cell compartmental redox
balance via the malate–aspartate shuttle (MAS) (Figure 1). The net effect of the MAS is to
recycle NADH produced in the cytosol (predominantly from glycolysis) back to NAD+
and to transfer the reducing power generated in the cytosol to the mitochondrion for
oxidation via oxidative phosphorylation [23]. The MAS utilizes two cytosolic enzymes,
glutamic-oxaloacetic transaminase 1 (GOT1) and malate dehydrogenase 1 (MDH1), to
convert aspartate to malate, NADH to NAD+, and alpha-ketoglutarate (aKG; also known
as 2-oxoglutarate) to glutamate. It utilizes another two enzymes in the mitochondria, GOT2
and MDH2, which in a fashion that is parallel and reverse to the cytosolic reaction, convert
malate to aspartate, NAD+ to NADH, and aKG to glutamate [5]. The MAS also requires
two antiporters on the mitochondrial inner membrane to transport the metabolites in and
out of the mitochondria [23]. Evidence suggests that disruption of the MAS may decrease
the cytosolic NAD+/NADH ratio and increase the mitochondrial NAD+/NADH ratio,
which could lead to rippling effects on other metabolic pathways [9]. Moreover, some
cancer types, such as those carrying PI3KCA mutations, appear to be more sensitive to
MAS perturbation than others [24,25].
Interestingly, in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) cells, aspar-
tate also plays an important role in maintaining redox homeostasis by supporting NADPH
production [26] (Figure 1). As discussed above, aspartate is an important source for malate
in the cytosol. In PDAC cells, malate is utilized by NADP-dependent malic enzyme 1 (ME1)
to generate pyruvate and NADPH. Inhibition of any step in the production and utilization
of cytosolic malate leads to a decrease in the NADPH/NADP+ ratio, an increase in reactive
oxygen species (ROS), and a significant reduction in clonogenic growth of KRAS mutant
cells [26]. Thus, once again, this study highlights the multifaceted roles of aspartate in
governing cancer cell growth and survival.
3. Aspartate Availability, Biosynthesis, and Their Limiting Steps in Cancer
To target aspartate availability in cancer, it is important to know how intracellular
aspartate level is supported. Aspartate concentration in human plasma is low, ranging
between 0 and 68 µM [27]. Some cancer cells have the ability to acquire aspartate from the
environment via the expression of low- or high-affinity aspartate membrane transporters,
such as SLC1A2 and SLC1A3, or via macropinocytosis [8,28]. For instance, it has been
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shown that endocrine-resistant estrogen receptor-positive (ER+) breast cancer cells can
import aspartate and glutamate, which contributes to their aggressive phenotypes and
resistance to endocrine therapy [10]. For these cancer types, aspartate availability may
be suppressed by targeting the expression or the activities of aspartate membrane trans-
porters [10]. For others, it may be possible to devise an effective targeted approach by
identifying the limiting steps in their respective aspartate biosynthesis pathways.
3.1. Aspartate Biosynthesis in Respiration-Competent Cancers
In cells exhibiting mitochondrial respiration competency, aspartate is mainly syn-
thesized in the mitochondria by GOT2 from glutamate and the TCA cycle metabolite
oxaloacetate [5] (Figure 2A,B, right). Many cancer types use glutamine to fuel the TCA
cycle [4,29]. Therefore, inhibition of glutaminase-1 (GLS1), the first step in glutaminolysis,
in cancers displaying glutamine dependency may lead to aspartate deprivation. Indeed,
while inhibition of GLS1 reduces aspartate production and the proliferation of von Hippel–
Lindau (VHL)−/− renal cell carcinoma (RCC) cells, VHL+/+ cells can adapt by increasing
glucose contribution to the TCA cycle and aspartate biosynthesis [12]. These results demon-
strate that aspartate depletion can exert potent anticancer effects; however, it is critical
that aspartate-targeting approaches should be tailored based on the specific metabolic
constraints of individual cancer types.




Figure 2. Aspartate biosynthetic pathways under different cell states. (A) Aspartate can be produced by glutamic-oxaloa-
cetic transaminase (GOT) 1 or 2, which carries out the reversible reactions from oxaloacetate and glutamate to aspartate 
and alpha-ketoglutarate. (B) Aspartate biosynthetic pathways are determined by cell state, i.e., cell respiration and mito-
chondrial metabolism. The diagrams depict the enzymes and intermediates (shown by colored dots) involved in aspartate 
biosynthesis under respiration-competent (right panel) and respiration-incompetent (left panel) conditions. ACLY, ATP-
citrate lyase; GOT1 or 2, glutamic-oxaloacetic transaminase 1 or 2; GLS1, glutaminase 1; MDH1, malate dehydrogenase 1; 
PC, pyruvate carboxylase. 
Interestingly, it has been known for a long time that respiration-deficient cancer cells 
can proliferate in pyruvate-containing media [40]. Pyruvate can also confer resistance to 
OXPHOS inhibitors, implicating the presence of an alternative pathway for aspartate bio-
synthesis under respiration-incompetent conditions [11]. Indeed, Birsoy et al. showed 
that, in respiration-deficient cells, flux through GOT1 is reversed, so that it can generate 
aspartate using glutamate and oxaloacetate in the cytosol [5] (Figure 2A,B, left). In the 
absence of mitochondrial oxidative metabolism, oxaloacetate may be derived from three 
potential sources (Figure 2B, left). First, pyruvate can give rise to oxaloacetate via PC. In 
SDH-null cells, PC plays a pivotal role in supporting aspartate biosynthesis and cell pro-
liferation [41]. Second, malate can give rise to oxaloacetate via MDH1 using NAD+ as the 
electron acceptor. Pyruvate may stimulate this reaction by recycling NADH to NAD+ via 
lactate dehydrogenase (LDH). In MDH1 knockout cells, pyruvate can no longer restore 
aspartate level in the presence of OXPHOS inhibitors [5]. Third, citrate can give rise to 
oxaloacetate via ATP-citrate lyase (ACLY). As citrate is generated predominantly by glu-
taminolysis and reductive carboxylation in respiration-impaired cells [42–44], glutamine 
utilization may also play a role in maintaining aspartate level in these cells. 
Notably, essentially all of the metabolic routes described above require GOT1 for 
generating aspartate under respiration incompetency. While GOT1-null cells can prolifer-
ate under respiration-competent conditions, they cannot survive OXPHOS inhibition even 
with pyruvate supplementation [5]. These findings strongly suggest that GOT1 may be a 
prime target against cancers exhibiting respiration incompetency. 
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Figure 2. Aspartate biosynthetic pathways under different cell states. (A) Aspartate can be produced by glutamic-
oxaloacetic transaminase (GOT) 1 or 2, which carries out the reversible reactions from oxaloacetate and glutamate to
aspartate and alpha-ketoglutarate. (B) Aspartate biosynthetic pathways are determined by cell state, i.e., cell respiration
and mitochondrial metabolism. The diagrams depict the enzymes and intermediates (shown by colored dots) involved
in aspartate biosynthesis under respiration-competent (right panel) and respiration-incompetent (left panel) conditions.
ACLY, ATP-citrate lyase; GOT1 or 2, glutamic-oxaloacetic transaminase 1 or 2; GLS1, glutaminase 1; MDH1, malate
dehydrogenase 1; PC, pyruvate carboxylase.
In addition, oxaloacetate can be derived from pyruvate via pyruvate carboxylase
(PC) (Figure 2B, right). A human study found that PC is overexpressed and activated in
tumors of early-stage non-small cell lung cancer (NSCLC) as compared to normal lung
tissues [30]. Its expression also correlates positively with advanced stages of human breast
cancer samples and with breast cancer-derived lung metastases in a mouse model [31,32].
Importantly, genetic knockdown or pharmacological inhibition of PC in NSCLC and breast
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cancer cell lines can decrease TCA cycle metabolites, aspartate levels, cell proliferation, and
the progression of xenograft tumors in mice [30,31,33]. These findings suggest that PC may
be a promising target for aspartate depletion in NSCLC and late-stage breast cancer.
3.2. Aspartate Biosynthesis in Respiration-Incompetent Cancers
Respiration incompetency is a feature of some of the most aggressive cancer types,
such as ones carrying mutations in the TCA cycle enzymes fumarate hydratase (FH)
and succinate dehydrogenase (SDH) [34–37]. Tumor hypoxia or mitochondrial DNA
mutations can also induce varying degrees of respiration deficiency in a wide range of
cancer types [8,38]. Inhibition of mitochondrial respiration, either inducibly or inherently,
can in turn cause a suppression of mitochondrial oxidative metabolism, resulting in a
significant reduction in mitochondrial aspartate production [6,11]. Concordantly, aspartate
is a major limiting factor for cancer cell proliferation under hypoxia or ETC inhibition both
in vitro and in vivo [5,6,8,11,39].
Interestingly, it has been known for a long time that respiration-deficient cancer cells
can proliferate in pyruvate-containing media [40]. Pyruvate can also confer resistance
to OXPHOS inhibitors, implicating the presence of an alternative pathway for aspartate
biosynthesis under respiration-incompetent conditions [11]. Indeed, Birsoy et al. showed
that, in respiration-deficient cells, flux through GOT1 is reversed, so that it can generate
aspartate using glutamate and oxaloacetate in the cytosol [5] (Figure 2A,B, left). In the
absence of mitochondrial oxidative metabolism, oxaloacetate may be derived from three
potential sources (Figure 2B, left). First, pyruvate can give rise to oxaloacetate via PC.
In SDH-null cells, PC plays a pivotal role in supporting aspartate biosynthesis and cell
proliferation [41]. Second, malate can give rise to oxaloacetate via MDH1 using NAD+
as the electron acceptor. Pyruvate may stimulate this reaction by recycling NADH to
NAD+ via lactate dehydrogenase (LDH). In MDH1 knockout cells, pyruvate can no longer
restore aspartate level in the presence of OXPHOS inhibitors [5]. Third, citrate can give
rise to oxaloacetate via ATP-citrate lyase (ACLY). As citrate is generated predominantly by
glutaminolysis and reductive carboxylation in respiration-impaired cells [42–44], glutamine
utilization may also play a role in maintaining aspartate level in these cells.
Notably, essentially all of the metabolic routes described above require GOT1 for
generating aspartate under respiration incompetency. While GOT1-null cells can proliferate
under respiration-competent conditions, they cannot survive OXPHOS inhibition even
with pyruvate supplementation [5]. These findings strongly suggest that GOT1 may be a
prime target against cancers exhibiting respiration incompetency.
4. Therapeutic Approaches Targeting Aspartate Availability in Cancer
Various therapeutic approaches discussed herein are summarized in Table 1.
Table 1. Therapeutic approaches that deplete aspartate in cancer cells.
Therapeutic Agent Proposed Mechanism ofAction
Status of
Development Co-Targeting Strategy References
CB-839 Inhibit GLS1 clinical trial Inhibit poly(ADP-ribose)polymerase (PARP) [12]
Metformin Inhibit Complex I of theelectron transport chain
FDA-approved
diabetes drug
Inhibit GOT1 or exploit GOT1
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4.1. Glutaminase Inhibition Reduces Glutamine Utilization and Aspartate Synthesis
Glutamine is the most abundant amino acid in human plasma [4] and enters cells
via a number of cell membrane transporters [47]. Many canonical oncogenes, including
MYC and KRAS, elicit glutamine dependency [4]. Upregulation of glutamine metabolism
may also contribute to anticancer treatment resistance [48,49]. Thus, pharmacological
inhibition of GLS1 is an area under intensive investigation [50]. CB-839 is presently the
most advanced GLS1 inhibitor in clinical development with more than a dozen Phase
II combination trials underway (https://www.clinicaltrials.gov, accessed on 17 October
2021). CB-839 significantly abates aspartate in VHL-mutated RCC cells and chemoresistant
ovarian cancer cells, consistent with the role of glutamine as the major fuel for the TCA cycle
in these cells [12,49]. One of these studies further shows that aspartate depletion leads to
nucleotide deficiency and DNA replication stress, consequently sensitizing CB-839-treated
cells to poly (ADP-ribose) polymerase (PARP) inhibition [12]. These results demonstrate
that aspartate depletion is an important mechanism by which glutaminase inhibitors exert
anticancer effects (Figure 3). They further imply that cancers may develop resistance to
GLS1 inhibitors if they can use other means to boost aspartate availability. Indeed, p53 can
contribute to cancer cell adaptation to glutamine deprivation by promoting the expression
of the aspartate transporter SLC1A3 [51]. Nonetheless, pathways that are particularly
important for cell survival when aspartate level is low, such as PARP-mediated DNA repair,
remain an attractive combination therapy target in conjunction with glutaminase inhibitors.
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4.2. OXPHOS Inhibition Suppresses Mitochondrial Metabolism and Aspartate Synthesis 
OXPHOS inhibitors are promising anticancer therapeutics because they have been 
shown to suppress the growth of a wide spectrum of cancer cell lines in culture and in 
preclinical mouse models [52,53]. In addition, some cancer types, such as RB1-deficient 
breast cancers, KRAS-driven cancers, and chemoresistant melanoma, are particularly re-
liant on OXPHOS activity and are especially sensitive to OXPHOS inhibition [54–56]. 
Thus, there are nearly a dozen OXPHOS inhibitors being investigated in the clinic and 
more being developed in laboratories for cancer treatment [52]. Among them, the antidi-
abetic drug metformin is the most studied, with over 100 ongoing clinical trials [57]. Epi-
demiological and clinical studies suggest that metformin decreases cancer risk when 
given in the absence of a cancer diagnosis and increases the survival rate of cancer patients 
[1,52,57]. While normalization of blood glucose and insulin levels may partially account 
for metformin’s anticancer effects, it is clear that metformin can directly suppress tumor 
growth via ETC complex I inhibition [58]. Although OXPHOS deficiency can lead to bio-
energetic catastrophe in glucose-limited conditions [59], data from cell culture and mouse 
xenograft tumor models strongly suggest that, in normal glucose conditions, aspartate 
availability is a major determinant of cancer cell susceptibility to metformin and other 
OXPHOS inhibitors [5,6,8,11,39] (Figure 3). Therefore, a number of factors likely influence 
the therapeutic efficacy of OXPHOS inhibitors, including cellular import of aspartate and 
alternative metabolic pathways that maintain NAD+ level and thereby support aspartate 
biosynthesis under respiration deficiency. It is also possible that some cancer cells, under 
aspartate limitation, restrict aspartate utilization by certain metabolic pathways in order 
to conserve aspartate to prioritize supporting nucleotide synthesis [21]. Therefore, in the 
























































Figure 3. Therapeutic opportunities for abrogating aspartate availability. Protein targets (in red letters, unboxed) and
chemical agents (in red letters, box d) that have already been demonstrated to deplete a partate in cancer cells or mouse
models are shown. Metformin and chloroquine suppress the TCA cycle indirectly. aKG, alpha-ketoglutarate; ACLY, ATP-
citrate lyase; GOT1 or 2, glutamic-oxaloacetic transaminase 1 or 2; GLS1, glutaminase 1; MDH1, malate dehydrogenase 1;
OGDH, oxoglutarate dehydrogenase; PC, pyruvate carboxylase.
4.2. OXPHOS Inhibition Suppresses Mitochondrial Metabolism and Aspartate Synthesis
OXPHOS inhibitors are promising anticancer therapeutics because they have been
shown to suppress the growth of a wide spectrum of cancer cell lines in culture and in pre-
clinical mouse models [52,53]. In addition, some cancer types, such as RB1-deficient breast
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cancers, KRAS-driven cancers, and chemoresistant melanoma, are particularly reliant on
OXPHOS activity and are especially sensitive to OXPHOS inhibition [54–56]. Thus, there
are nearly a dozen OXPHOS inhibitors being investigated in the clinic and more being
developed in laboratories for cancer treatment [52]. Among them, the antidiabetic drug
metformin is the most studied, with over 100 ongoing clinical trials [57]. Epidemiologi-
cal and clinical studies suggest that metformin decreases cancer risk when given in the
absence of a cancer diagnosis and increases the survival rate of cancer patients [1,52,57].
While normalization of blood glucose and insulin levels may partially account for met-
formin’s anticancer effects, it is clear that metformin can directly suppress tumor growth
via ETC complex I inhibition [58]. Although OXPHOS deficiency can lead to bioener-
getic catastrophe in glucose-limited conditions [59], data from cell culture and mouse
xenograft tumor models strongly suggest that, in normal glucose conditions, aspartate
availability is a major determinant of cancer cell susceptibility to metformin and other
OXPHOS inhibitors [5,6,8,11,39] (Figure 3). Therefore, a number of factors likely influence
the therapeutic efficacy of OXPHOS inhibitors, including cellular import of aspartate and
alternative metabolic pathways that maintain NAD+ level and thereby support aspartate
biosynthesis under respiration deficiency. It is also possible that some cancer cells, under
aspartate limitation, restrict aspartate utilization by certain metabolic pathways in order
to conserve aspartate to prioritize supporting nucleotide synthesis [21]. Therefore, in the
clinic, OXPHOS inhibition alone may not be sufficiently effective in most cancer types. It
is important to note that the aspartate level of a cell is the key determinant of whether it
will proliferate, enter cell cycle arrest, or die in response to compromised ETC activity [5].
Thus, as further discussed below, investigation of additional strategies to robustly reduce
aspartate levels in combination with OXPHOS inhibitors are expected to generate more
broadly applicable anticancer approaches.
4.3. aKG Depletes Aspartate via GOT1 under Respiration-Incompetent Cancer Conditions
Respiration incompetency plays a natural and critical role in the tumorigenesis of
many malignancies, including cancers caused by FH and SDH mutations [34–36], cancers
harboring pathogenic mitochondrial DNA mutations [38], or cancers residing in hypoxic
environments [8]. In these cancer conditions, respiration deficiency can lead to metabolic
rewiring in which GOT1 becomes the main aspartate producer [5] (Figure 2A,B, left). By
examining a collection of snap-frozen human glioblastoma samples, Garcia-Bermudez et al.
found that hypoxic tumors exhibit significantly reduced aspartate levels [8]. Moreover,
several studies have shown that cells harboring mutations in FH, SDH, or the ETC complex
III cytochrome b gene (CYTB) possess much lower aspartate levels compared to otherwise
isogenic cells that do not carry these mutations [14,41]. Considering that respiration-
incompetent cancer types are typically aggressive and refractory to standard anticancer
therapies, their metabolic constraints in aspartate biosynthesis may represent a new thera-
peutic opportunity.
Using multiple respiration-competent and -incompetent cancer cell pairs, Madala et al.
identified that, at low millimolar concentrations, cell-permeable alpha-ketoglutarate (aKG)
diesters induce potent cell death selectively in respiration-incompetent cells [14] (Figure 3).
The proposed mechanism resulting in the specificity of this class of compounds is intriguing.
The study shows that treatment with dimethyl alpha-ketoglutarate (dmaKG) leads to a
surge of intracellular aKG, a key TCA cycle intermediate. While aKG accumulation subsides
rapidly due to mitochondrial oxidative metabolism under respiration-competent cancer
conditions, aKG might not be metabolized as efficiently under respiration incompetency.
Consequently, a high concentration of aKG in the cytosol of respiration-incompetent cells
reverses the flux of GOT1, switching the role of GOT1 from synthesis to depletion of
aspartate in these cells [14]. The action of dmaKG is unique and different from other agents
that target GOT. In contrast to treatment with the GOT1/2 inhibitor aminooxyacetic acid
(AOA), which decreases aspartate level and suppresses cell proliferation indiscriminately
between respiration-competent and -incompetent cells, dmaKG exhausts aspartate to a
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cytotoxic level selectively in respiration-incompetent cells [14]. In preclinical mouse models,
dmaKG displays a promising biosafety profile as well as encouraging anticancer efficacy
and specificity [14]. In light of these findings, future clinical investigations of dmaKG
as a targeted therapy for various respiration-incompetent cancer types and conditions
are warranted.
Interestingly, dmaKG can also synergize with OXPHOS inhibitors to induce cytotoxic-
ity in a wide range of respiration-competent cancer cell types [14,45]. A 2-week combined
treatment with dmaKG and phenformin (a membrane-permeable analog of metformin)
abolishes tumor progression and suppresses aspartate levels in xenograft tumors, but not in
mouse organs, revealing a potential therapeutic window for this combination therapy [14].
As some emerging clinical evidence suggests that OXPHOS inhibition alone may not pro-
vide as significant a therapeutic benefit as originally hoped [45], further exploration of
dmaKG and OXPHOS inhibitor combination therapy may prove useful.
4.4. Knockdown of Oxoglutarate Dehydrogenase (OGDH) Reduces Aspartate Level in Subsets
of Cancers
OGDH is the E1 subunit of the mitochondrial alpha-ketoglutarate dehydrogenase
complex (KGDHC), which catalyzes oxidative decarboxylation of aKG. Two groups have
independently identified different subsets of cancer cell lines that are highly sensitive to
OGDH knockdown, including those harboring PIK3CA mutations [24,25]. Importantly,
both studies show that OGDH knockdown results in a strong reduction of aspartate
level accompanied by a decrease in the NAD+/NADH ratio in the sensitive cell types
(Figure 3). The authors conclude that OGDH-dependent cancer cell lines demonstrate
a profound reliance on the malate-aspartate shuttle, which makes them vulnerable to
aspartate deprivation [24,25]. Interestingly, Ilic et al. showed that PIK3CA mutant cancers
exhibit dmaKG sensitivity, suggesting that elevation of aKG level upon OGDH knockdown
may be the cause of aspartate depletion in these cells [25]. Notably, treatment with two
known chemical inhibitors of KGDHC, succinyl phosphonate (SP) and CPI-613, did not
exert similar effects to OGDH knockdown [24]. Thus, a pharmacological approach targeting
OGDH dependency in these subsets of cancers is still lacking. Nonetheless, the results from
Ilic et al. suggest that OGDH-dependent cancer types may also be susceptible to dmaKG
treatment [25].
4.5. Lysosomal Inhibition by Chloroquine Causes Aspartate Depletion
Anticancer effects of the antimalarial drug chloroquine (CQ) have been reported
in multiple cancer types [60]. CQ suppresses cancer cell growth by inhibiting nutrient
acquisition and recycling processes, such as autophagy and macropinocytosis, via lyso-
somal deacidification [60]. Surprisingly, two groups have concordantly shown that, in
pancreatic ductal adenocarcinoma (PDAC) and hepatoblastoma, treatment with CQ led
to a significant reduction of aspartate levels, whereas the other amino acids were largely
unaffected [15,46]. In cell culture, aspartate supplementation reversed CQ-mediated DNA
replication stress and cell death, suggesting that aspartate deprivation plays a crucial role
in CQ’s anticancer effects [15,46]. Overexpression of SLC1A3 also reversed CQ’s effect in a
xenograft tumor mouse model [15]. The mechanism by which CQ reduces aspartate level
is presently unknown, although some evidence suggests that mitochondrial metabolism
might be inhibited in CQ-treated cells [15] (Figure 3). Thus, it will be interesting to see
whether these findings can be extended to other CQ-sensitive cancer types, and to further
understand CQ’s mode of action in aspartate depletion. While clear anticancer effects
of CQ have been observed in experimental models, thus far its clinical efficacy has been
limited [61]. Results from Elliott et al. using a mouse model suggest that inhibition of the
replication stress response (RSR) pathway by VE-822, an inhibitor of ataxia telangiectasia
and Rad3-related protein (ATR) that is currently under clinical investigations, may improve
the therapeutic efficacy of CQ [15].
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5. Conclusions
Cancer cells exhibit a range of distinct metabolic phenotypes and metabolic constraints,
which in principle could be leveraged for therapeutic benefit by starving cancer cells of
essential nutrients. Development and evaluation of metabolically-targeted anticancer
agents, however, has revealed that in many cases response to therapy is less robust than
expected, both in animal models and in the clinic. One contributing factor is metabolic
plasticity, whereby cancer cells can engage alternative pathways to meet their specific
metabolic needs. Even so, some constraints may be insurmountable due to inflexibility
imposed by genetic or environmental factors. Here, we have described the multiple critical
roles of aspartate that have nominated aspartate uptake and biosynthesis pathways as
potential therapeutic targets in cancer. Notably, several different anticancer agents that
were originally designed with a different therapeutic rationale and target in mind in
fact lead to depletion of aspartate. Cancer cells that can acquire or synthesize aspartate
by compensatory means may have a particular adaptive survival advantage. Thus, co-
targeting aspartate availability could enhance therapeutic efficacy, including of OXPHOS
inhibitors. These concepts have now been shown in various preclinical models, and the
time is ripe to move the most promising combinatorial approaches towards the clinic.
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